期刊文献+

醋酸钙治疗维持性血液透析患者高磷血症的疗效观察 被引量:3

Observation on curative effects of calcium acetate on hyperphosphatemia of patients receiving maintenance hemodialysis
下载PDF
导出
摘要 目的探讨醋酸钙对维持性血液透析患者高磷血症的治疗效果。方法将84例血液透析高磷血症患者随机分为治疗组(n=43)和对照组(n=41),治疗组给予餐中口服醋酸钙,9片/d;对照组给予餐中口服碳酸钙,9片/d,疗程共12 w,分别于治疗前及治疗后每2 w,检测两组透析前的血钙、磷、i PTH水平。结果两组血磷水平于治疗开始后均逐渐下降,自治疗4 w起,治疗组血磷水平均低于对照组(P<0.05)。治疗前,两组血钙水平正常,治疗后两组血钙水平均随口服药物时间增长而升高,至6 w后血钙水平趋于稳定,自治疗4 w起,对照组血钙水平均明显高于治疗组(P<0.05)。两组血i PTH水平在12 w观察期内无显著差异(P>0.05)。结论口服醋酸钙可有效降低维持性血液透析高磷血症患者血磷水平,减少高钙血症风险,值得临床推广应用。 Objective To investigate the curative effect of calcium acetate on hyperphosphatemia of patients receiving maintenance hemodialysis, Methods 84 cases of hyperphosphatemia that received maintenance hemodialysis were randomly divided into treatment group (n=43) and control group (n=41). The treatment group was given calcium acetate 9 pieces/d during the meal, and the control group was given calcium carbonate 9 pieces/d. The course of treatment was 12 weeks. The blood calcium, phosphorus, and the entire section iPTH levels before the dialysis were detected every two weeks before and after the treatment, Results The blood phosphorus levels in both groups decreased after the beginning of the treatment. Since the fourth week of the treatment, the blood phosphorus levels in the treatment group were lower than those in the control group(P 〈 0.05). Before the treatment, the blood calcium levels in both groups were normal; after the treatment, those levels increased with the time of oral administration. Since the 6th week, the blood calcium levels were stable. After the 4th week of treatment, the blood calcium levels in the control group were significantly higher than those in the treatment group (P 〈 0.05). There was no significant difference in the iPTH levels between the two groups in the observation period of 12 weeks (P 〉 0.05). Conclusion Oral administration with calcium acetate can effectively reduce the blood phosphorus levels of patients with hypercalcemia who received maintenance hemodialysis and the risk of hypercalcemia. It is worthy of clinical application.
出处 《西南国防医药》 CAS 2015年第12期1289-1291,共3页 Medical Journal of National Defending Forces in Southwest China
关键词 醋酸钙 血液透析 高磷血症 疗效 calcium acetate hematodialysis hyperphosphatemia curative effect
  • 相关文献

参考文献6

  • 1Tominaga Y, Ma tsuoka S, Sato T. Surgical indications and procedures of parat hyroidectomy in patients with chronic kidney disease[J].Ther Apher Dial,2005,9(1):44-47. 被引量:1
  • 2Kong X, Zhang L, Zhang L, et al. Mineral and bone disorder in Chinese dialysis patients: a multicenter study [J].BMC Nephrol, 2012,13:116. 被引量:1
  • 3Palmer SC, Hayen A, Macaskill P, et al. Scrum levels of phosphorus, parathyroid hommone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis [J]. JAMA, 2011,305(11): 1119-1127. 被引量:1
  • 4Tonelli M,Pannu N,Manns B,et al. Oral phosphate binders in patients with kidney failure [J]. N Engl J Med,2010,362(114): 1312-1324. 被引量:1
  • 5陆任华,倪兆慧,钱家麒,张政,袁伟杰,戎殳,梅长林,宦红娣,张景红,尤莉,陈靖,郝传明,范伟峰,牛建英,顾勇,刘毅,徐玉兰,陆玮,蒋更如,盛晓华,汪年松,陈晓农,陈楠.醋酸钙治疗血液透析患者高磷血症的有效性与安全性[J].中华肾脏病杂志,2013,29(6):429-434. 被引量:30
  • 6刘琦.醋酸钙及碳酸钙治疗维持性血液透析患者高磷血症的短期疗效观察[J].浙江医学,2013,35(8):672-674. 被引量:10

二级参考文献11

  • 1Goodman W G, Goldin J, Kuizon B D, et al. Coronary-artery cal- cification in young adults with end-stage renal disease who are undergoing dialysis[J]. N Engl J Med, 2000,342(20): 1478-1483. 被引量:1
  • 2Lezaic V, Tirmenstajn-Jankovic B, Bukvic D, et al. Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification[J]. Clin Nephrol,2009,71 (1):21-29. 被引量:1
  • 3Achinger S G, Ayus J C. Left ventricular hypertrophy: is hyper- phosphatemia among dialysis patients a risk factor[J].J Am Soc Nephrol,2006,17(3):255-261. 被引量:1
  • 4Tonelli M, Pannu N, Manns B, et al. Oral phosphate binders in patients with kidney failure[J]. N Engl J Meal, 2010, 362 (14):1312- 1324. 被引量:1
  • 5Pflanz S, Henderson I S, McEIduff N, et al. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic hemodialysis[J]. Nephrol Dial Transplant, 1994,9(8): 1121 - 1124. 被引量:1
  • 6Evenepoel P, Selgas R, Caputo F, et al. Efficacy and safety of sevetamer hydrochloride and calcium acetate in patients on peritoneal dialysis[J]. Nephrol Dial Transplant,2009,24(1):278- 285. 被引量:1
  • 7Waliot M,Bonzel K E,Winter A,et al.Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients[J]. Pediatr Nephrol,1996,10(5): 625-630. 被引量:1
  • 8D Almeida Filho E J, Da Cruz E A, Hoette M, et al. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodiatysis patients[J]. Sao Paulo Med J,2000,118 (6):179-184. 被引量:1
  • 9刘俊.维持性血液透析患者的降磷治疗[J].实用医学杂志,2011,27(22):3998-3999. 被引量:11
  • 10王梦婧,陈靖.磷代谢与慢性肾脏病[J].肾脏病与透析肾移植杂志,2011,20(6):548-553. 被引量:10

共引文献32

同被引文献31

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部